CYMEVENE Powder for concentrate for solution (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Cymevene 500 mg powder for concentrate for solution for infusion.
Qualitative and quantitative composition
Each vial contains 500 mg of ganciclovir (as ganciclovir sodium). After reconstitution with 10 mL of water for injections, each mL provides 50 mg of ganciclovir. Excipient(s) with known effect: approximately ...
Pharmaceutical form
Powder for concentrate for solution for infusion (powder for concentrate). White to off-white solid cake.
Therapeutic indications
Cymevene is indicated in adults and adolescents ≥12 years of age for the: treatment of cytomegalovirus (CMV) disease in immunocompromised patients; prevention of CMV disease using pre-emptive therapy in ...
Posology and method of administration
Posology Treatment of CMV disease Adults and Paediatric Population ≥12 years of age with normal renal function Induction treatment: 5 mg/kg given as an intravenous infusion over one hour, every 12 hours ...
Contraindications
Hypersensitivity to the active substance or valganciclovir or to any of the excipients listed in section 6.1. Breast-feeding (see section 4.6).
Special warnings and precautions for use
Cross-hypersensitivity Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and penciclovir, a cross-hypersensitivity reaction between these drugs is possible. Caution should ...
Interaction with other medicinal products and other forms of interaction
Pharmacokinetic interactions Probenecid Probenecid given with oral ganciclovir resulted in statistically decreased renal clearance of ganciclovir, and led to clinically significant increased exposure. ...
Fertility, pregnancy and lactation
Fertility A small clinical study with renal transplant patients receiving Valcyte for CMV prophylaxis for up to 200 days demonstrated an impact of valganciclovir/ganciclovir on spermatogenesis, with decreased ...
Effects on ability to drive and use machines
Ganciclovir may have a major influence on the ability to drive and use machines (see section 4.8).
Undesirable effects
Summary of the safety profile Valganciclovir is a pro-drug of ganciclovir, and adverse reactions associated with valganciclovir can be expected to occur with ganciclovir. Oral ganciclovir is no longer ...
Overdose
Symptoms Reports of overdoses with i.v. ganciclovir, some with fatal outcomes, have been received from clinical trials and during post-marketing experience. The majority of the reports were either not ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antivirals for systemic use, direct acting antivirals, nucleosides and nucleotides excluding reverse transcriptase inhibitors ATC code: J05AB06 Mechanism of action Ganciclovir ...
Pharmacokinetic properties
The systemic exposure (AUC<sub>0-∞</sub>) reported following dosing with a single 1-hour IV infusion of 5mg/kg ganciclovir in adult liver transplant patients was on average 50.6 µg.h/mL (CV% 40). In this ...
Preclinical safety data
Ganciclovir was mutagenic in mouse lymphoma cells and clastogenic in mammalian cells. Such results are consistent with the positive mouse carcinogenicity study with ganciclovir. Ganciclovir is a potential ...
List of excipients
Sodium hydroxide (for pH-adjustment) Hydrochloric acid (for pH-adjustment)
Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6. Do not use bacteriostatic water for injections containing ...
Shelf life
3 years. <u>After reconstitution:</u> Chemical and physical in-use stability has been demonstrated for the reconstituted product for 12 hours at 25°C after dissolving with water for injections. Do not ...
Special precautions for storage
This medicinal product does not require any special storage conditions. For storage conditions after reconstitution and after dilution of the medicinal product, see section 6.3.
Nature and contents of container
Single-dose glass vials of 10 mL with fluoro-resin laminated/siliconised rubber stopper and aluminum closure with flip-off cap. Available in packs of 1 vial or 5 vials. Not all pack sizes may be marketed. ...
Special precautions for disposal and other handling
Caution should be exercised in the handling of Cymevene. Since Cymevene is considered a potential teratogen and carcinogen in humans, caution should be observed in its handling. Avoid inhalation or direct ...
Marketing authorization holder
CHEPLAPHARM Arzneimittel GmbH, Ziegelhof 24, 17489 Greifswald, Germany
Marketing authorization number(s)
PL 27041/0013
Date of first authorization / renewal of the authorization
Date of first authorisation: 15 June 1988 Date of latest renewal: 28 April 2016
Date of revision of the text
15/02/2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
